This clinical trial aims to get better understanding of a possible treatment option for patients with non-small cell lung cancer (NSCLC). It includes an investigational treatment that is not approved for general use yet – before an investigational treatment can be approved, it needs to be studied in clinical trials like this one, so researchers and health authorities can understand how well it works, how safe it is and what are the side effects. The trial will include adult participants from multiple countries who have NSCLC and whose cancer cells have specific genetic mutations. These mutations affect the way the cancer cells grow and divide, as well as the way a person’s cancer responds to treatment. The trial is currently enrolling people whose tumors have a genetic mutation known as an “EGFR exon 20 insertion.”
Proud members and holders of:
